---
id: 167
title: Histoplasma capsulatum (Histoplasmosis)
category: organisms
subcategory: endemic_fungi
tags: [Histoplasma, histoplasmosis, Ohio-Mississippi-valleys, itraconazole, amphotericin, mediastinal-granuloma]
difficulty: medium
---

## Question

What are the key clinical syndromes and treatment of histoplasmosis? Use the **"Endemic (Ohio/Mississippi), Acute Pulmonary (Self-Limited), Disseminated (AIDS) → Itraconazole (Mild) or AmB (Severe)"** framework.

## Answer

### ***Histoplasma capsulatum* Overview:**

**Geography:**
- **Endemic:** Ohio/Mississippi River Valleys (US), Central/South America
- **Soil contaminated with bird/bat droppings** (caves, construction, demolition)

**Transmission:** Inhalation of microconidia (airborne spores)

### **Clinical Syndromes:**

**Acute Pulmonary Histoplasmosis (Most Common):**

**Presentation:**
- **Asymptomatic** (90% of infections)
- **Symptomatic (10%):** Flu-like illness (fever, cough, chest pain, headache, myalgia) 1-3 weeks after exposure
- **Heavy exposure:** More severe (pneumonia, mediastinal lymphadenopathy)

**CXR:**
- **Hilar/mediastinal lymphadenopathy**
- **Reticulonodular infiltrates**
- **Calcified granulomas** (healed infection, "buckshot" calcifications)

**Outcome:**
- **Self-limited** (2-4 weeks) in immunocompetent
- **Treatment usually NOT needed** unless severe

**Chronic Cavitary Pulmonary Histoplasmosis:**

**Risk Factors:**
- **Chronic lung disease** (COPD, emphysema)
- **Smoking**

**Presentation:**
- **Subacute/chronic** (weeks to months)
- **Cough, sputum production, weight loss, night sweats** (mimics TB)

**CXR:**
- **Upper lobe cavities** (similar to TB)
- **Progressive fibrosis**

**Treatment:**
- **Itraconazole 200mg PO TID × 3 days, then 200mg PO BID × 12-24 months**

**Progressive Disseminated Histoplasmosis (PDH):**

**Risk Factors:**
- **AIDS (CD4 <150)** - most common
- **Transplant, immunosuppression, TNF-α inhibitors**
- **Extremes of age** (infants, elderly)

**Presentation:**
- **Fever, weight loss, fatigue**
- **Hepatosplenomegaly, lymphadenopathy**
- **Pancytopenia** (bone marrow involvement)
- **Skin lesions:** Papules, nodules, ulcers (oral mucosa common in AIDS)
- **Adrenal insufficiency** (bilateral adrenal necrosis)
- **CNS involvement:** Meningitis, mass lesions (10-20%)

**Labs:**
- **Pancytopenia, ↑LDH, ↑ferritin** (markedly elevated)

**Outcome:**
- **Fatal without treatment**

**Mediastinal Complications:**

**Mediastinal Granuloma:**
- **Enlarged lymph nodes** → compress adjacent structures (SVC syndrome, esophageal obstruction)
- **Usually self-limited**, observation

**Mediastinal Fibrosis (Fibrosing Mediastinitis):**
- **Excessive fibrotic response** (rare, <5% of infections)
- **Progressive compression:** SVC syndrome, pulmonary vein/artery obstruction
- **NO effective treatment** (antifungals ineffective, surgery high-risk)

### **Diagnosis:**

**Histopathology:**
- **Small intracellular yeast** (2-5 μm, within macrophages)
- **GMS or PAS stain** (silver stain)

**Culture:**
- **Gold standard** (slow, 2-6 weeks)
- **Blood, bone marrow, sputum, tissue**

**Antigen Detection (Preferred for Disseminated):**
- **Urine/serum *Histoplasma* antigen** (EIA)
- **Sensitivity:** >90% (disseminated), 75-85% (acute pulmonary)
- **Cross-reacts:** *Blastomyces*, *Coccidioides* (may need follow-up testing)

**Serology:**
- **Complement fixation (CF), immunodiffusion (ID)**
- **Positive in 80-90%** (acute/chronic pulmonary)
- **NOT useful in immunocompromised** (blunted antibody response)

### **Treatment:**

**Acute Pulmonary (Symptomatic >4 Weeks or Severe):**
- **Itraconazole 200mg PO TID × 3 days, then 200mg PO BID × 6-12 weeks**

**Chronic Cavitary:**
- **Itraconazole 200mg PO TID × 3 days, then 200mg PO BID × 12-24 months**

**Progressive Disseminated (Moderate-Severe):**
- **Liposomal amphotericin B 3 mg/kg IV daily × 1-2 weeks** (until clinically improved)
- **Then:** **Itraconazole 200mg PO TID × 3 days, then 200mg PO BID × ≥12 months**
- **Monitor:** Urine *Histoplasma* antigen (should decline with treatment)

**Progressive Disseminated (Mild):**
- **Itraconazole 200mg PO TID × 3 days, then 200mg PO BID × 12 months**

**CNS Involvement:**
- **Liposomal amphotericin B 5 mg/kg IV daily × 4-6 weeks**
- **Then:** **Itraconazole 200mg PO BID-TID × ≥12 months**

**AIDS Patients:**
- **Start ART** after 2 weeks of antifungal (reduce IRIS risk)
- **Secondary prophylaxis:** Itraconazole 200mg PO daily until CD4 >150 × 6 months on ART

**Itraconazole Monitoring:**
- **Check levels** (trough 1-2 mcg/mL)
- **Drug interactions** (CYP3A4 inhibitor)

## Key Points

### **Endemic Geography:**
- **Ohio/Mississippi River Valleys** (US)
- **Bird/bat droppings** (caves, construction, demolition)

### **Acute Pulmonary = Self-Limited:**
- **90% asymptomatic**, 10% flu-like illness
- **Treatment NOT needed** unless severe or >4 weeks

### **Disseminated = AIDS CD4 <150:**
- **Fever, pancytopenia, hepatosplenomegaly**
- **Markedly elevated ferritin** (>1000 ng/mL, can be >10,000)
- **AmB × 1-2 weeks → itraconazole × ≥12 months**

### **Urine Antigen = Best Test (Disseminated):**
- **>90% sensitivity** in disseminated disease
- **Monitor response** (levels decline with treatment)
- **Cross-reacts** with *Blasto*, *Cocci*

### **Chronic Cavitary = Mimics TB:**
- **Upper lobe cavities** in COPD patient
- **Itraconazole × 12-24 months**

### **Mediastinal Fibrosis = No Treatment:**
- **Excessive fibrosis** (SVC syndrome, vascular obstruction)
- **Antifungals ineffective** (post-inflammatory fibrosis)
- **Surgery high-risk**

### **Clinical Pearls:**
- **Endemic:** Ohio/Mississippi River Valleys (bird/bat droppings, caves)
- **Acute pulmonary:** Self-limited (no treatment needed unless severe)
- **Disseminated (AIDS CD4 <150):** Fever, pancytopenia, ↑↑ferritin → AmB → itraconazole ≥12 months
- **Urine antigen** best test for disseminated
- **Chronic cavitary:** Upper lobe cavities (mimics TB) → itraconazole × 12-24 months

## Sources

- [IDSA: Histoplasmosis Guidelines 2024]
- [CID: Histoplasmosis in HIV 2024]

## Media

N/A
